Dr. Sauter on CAR T Cells in Real-World Patients With Hematologic Malignancies

Video

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor (CAR) T-cell therapy.

Patients are often faced with side effects such as severe cytopenia for long periods of time, says Sauter. If patients fail CAR T-cell therapy, further therapy becomes challenging. When patients progress, they must receive cytotoxic therapy with adequate hematopoietic reserve to tolerate the CAR T cells.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.